This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Center for Advancing Translational Sciences receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.

Complete applications for a license that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain confidential business information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: September 26, 2025.

**Joni Rutter,**

*Director, National Center for Advancing Translational Sciences, National Institutes of Health.*

[FR Doc. 2025–19199 Filed 10–1–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Heart, Lung, and Blood Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Advisory Council, October 29, 2025, 8:30 a.m. to 5:00 p.m., National Institutes of Health, Claude D. Pepper Building, 31 Center Drive, Bethesda, MD, 20894, which was published in the **Federal Register** on September 17, 2025, FR 2025–17998, 90 FRN 44834.

The National Heart, Lung, and Blood Advisory Council open meeting is being amended due to change of the meeting times. The meeting will be held on October 29, 2025, from 9:30 a.m. to 5:00 p.m. This meeting is open to the public.

**Denise M. Santeufemio,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–19206 Filed 10–1–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Heart, Lung, and Blood Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Advisory Council, October 29, 2025, 8:00 a.m. to 8:30 a.m., National Institutes of Health, Claude D. Pepper Building, 31 Center Drive, Bethesda, MD 20894, which was published in the **Federal Register** on September 17, 2025, FR 2025–17999, 90 FRN 44834.

The National Heart, Lung, and Blood Advisory Council closed meeting is being amended due to change of the meeting times. The meeting will be held on October 29, 2025, from 8:00 a.m. to 9:30 a.m. This meeting is closed to the public.

**Denise M. Santeufemio,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–19216 Filed 10–1–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### Government Owned Inventions Available for Licensing and/or Collaboration: Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), seeks research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells. This invention is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

**FOR FURTHER INFORMATION CONTACT:** Inquiries related to these licensing opportunities should be directed to Eric Cheng, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: *eric.cheng2@nih.gov* or Phone: 240–276–5978.

**SUPPLEMENTARY INFORMATION:** This technology includes an automated cell radiolabeling device that utilizes acoustophoresis microfluidic technology. The device streamlines the radiolabeling process by integrating cell washing and concentrating steps, which enhances reproducibility and standardization. This innovation simplifies the GMP (Good Manufacturing Practice) compliance for radiolabeling cells intended for human use. It also addresses the limitations of current manual methods that rely on centrifugation. The result is a benchtop system designed for clinical radio-pharmacies, ensuring efficient and reliable cell preparation for diagnostic and therapeutic applications.

This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404.

*NIH Reference Number:* E–096–2021.

*Product Type:* Device.

*Therapeutic Area(s):* Oncology.

*View Technology Webinar:* Automated Acoustophoresis Device to Radio-Label & Isolate Cells for Immunotherapy and Isolated Cells for Immunotherapy Treatment.

*Potential Commercial Applications:*

- Clinical radio-pharmacies for radiolabeled cell diagnostics.
- Research institutions focused on cellular therapies and diagnostics.
- Pharmaceutical companies developing radiolabeled therapeutics.

*Competitive Advantages:*

- Fully automated process reduces manual intervention, increasing efficiency and consistency.
- Micron-scale acoustophoresis technology enhances reproducibility and standardization of cell radiolabeling.
- Streamlined GMP compliance simplifies regulatory processes for clinical applications.
- Benchtop system.

*Publication:*

- Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure. (*https://jnm.snmjournals.org/content/63/supplement_2/2755*).

*Patent Status:* U.S. Patent Application 18/290,4425 filed on November 13, 2023, pending.

*Development Stage:* Prototype.

*Collaboration Opportunity:* Researchers at the NCI seek licensing